Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386886964> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W4386886964 abstract "Psoriasis, an inflammatory skin disease, is often treated with biologic therapeutics.To determine the real-world treatment effectiveness of risankizumab, an interleukin-23 inhibitor, in the treatment of moderate-to-severe plaque psoriasis.A retrospective, observational study was conducted using the CorEvitas Psoriasis Registry for eligible adults with a diagnosis of moderate-to-severe psoriasis and persistent use of risankizumab at 12 (±3) months after initiation. Skin clearance measures and patient-reported outcomes were analyzed for the entire study population and by prior biologic treatment.Among 287 patients with persistent risankizumab use at 1 year, most achieved clear or clear/almost clear skin and reported significant reductions in Dermatology Life Quality Index scores, psoriasis symptoms (fatigue, skin pain, and overall itch), and work and activity impairment.The CorEvitas Psoriasis Registry is not necessarily representative of all adults with psoriasis in the United States and Canada and does not measure patient adherence.Patients treated with risankizumab, regardless of prior treatment, achieved high levels of clear and clear/almost clear skin, Dermatology Life Quality Index scores of 0/1, and significant reductions in psoriasis symptoms (fatigue, skin pain, and overall itch) and work and activity impairment 1 year after initiation." @default.
- W4386886964 created "2023-09-21" @default.
- W4386886964 creator A5005718112 @default.
- W4386886964 creator A5016156797 @default.
- W4386886964 creator A5033903141 @default.
- W4386886964 creator A5035179840 @default.
- W4386886964 creator A5040462381 @default.
- W4386886964 creator A5043326530 @default.
- W4386886964 creator A5048801906 @default.
- W4386886964 creator A5057675915 @default.
- W4386886964 creator A5060819284 @default.
- W4386886964 creator A5091485944 @default.
- W4386886964 date "2023-09-01" @default.
- W4386886964 modified "2023-10-17" @default.
- W4386886964 title "Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis using the CorEvitas Psoriasis Registry" @default.
- W4386886964 cites W2558385573 @default.
- W4386886964 cites W2887412253 @default.
- W4386886964 cites W2955205003 @default.
- W4386886964 cites W3016827639 @default.
- W4386886964 cites W3028355101 @default.
- W4386886964 cites W3037060742 @default.
- W4386886964 cites W3092234193 @default.
- W4386886964 cites W3207194448 @default.
- W4386886964 cites W3217649772 @default.
- W4386886964 cites W4213058992 @default.
- W4386886964 doi "https://doi.org/10.1016/j.jaad.2023.08.097" @default.
- W4386886964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37739267" @default.
- W4386886964 hasPublicationYear "2023" @default.
- W4386886964 type Work @default.
- W4386886964 citedByCount "0" @default.
- W4386886964 crossrefType "journal-article" @default.
- W4386886964 hasAuthorship W4386886964A5005718112 @default.
- W4386886964 hasAuthorship W4386886964A5016156797 @default.
- W4386886964 hasAuthorship W4386886964A5033903141 @default.
- W4386886964 hasAuthorship W4386886964A5035179840 @default.
- W4386886964 hasAuthorship W4386886964A5040462381 @default.
- W4386886964 hasAuthorship W4386886964A5043326530 @default.
- W4386886964 hasAuthorship W4386886964A5048801906 @default.
- W4386886964 hasAuthorship W4386886964A5057675915 @default.
- W4386886964 hasAuthorship W4386886964A5060819284 @default.
- W4386886964 hasAuthorship W4386886964A5091485944 @default.
- W4386886964 hasConcept C126322002 @default.
- W4386886964 hasConcept C159110408 @default.
- W4386886964 hasConcept C16005928 @default.
- W4386886964 hasConcept C1862650 @default.
- W4386886964 hasConcept C23131810 @default.
- W4386886964 hasConcept C2776173921 @default.
- W4386886964 hasConcept C2777011040 @default.
- W4386886964 hasConcept C2779951463 @default.
- W4386886964 hasConcept C2780564577 @default.
- W4386886964 hasConcept C2908647359 @default.
- W4386886964 hasConcept C30036603 @default.
- W4386886964 hasConcept C71924100 @default.
- W4386886964 hasConcept C99454951 @default.
- W4386886964 hasConceptScore W4386886964C126322002 @default.
- W4386886964 hasConceptScore W4386886964C159110408 @default.
- W4386886964 hasConceptScore W4386886964C16005928 @default.
- W4386886964 hasConceptScore W4386886964C1862650 @default.
- W4386886964 hasConceptScore W4386886964C23131810 @default.
- W4386886964 hasConceptScore W4386886964C2776173921 @default.
- W4386886964 hasConceptScore W4386886964C2777011040 @default.
- W4386886964 hasConceptScore W4386886964C2779951463 @default.
- W4386886964 hasConceptScore W4386886964C2780564577 @default.
- W4386886964 hasConceptScore W4386886964C2908647359 @default.
- W4386886964 hasConceptScore W4386886964C30036603 @default.
- W4386886964 hasConceptScore W4386886964C71924100 @default.
- W4386886964 hasConceptScore W4386886964C99454951 @default.
- W4386886964 hasFunder F4320309117 @default.
- W4386886964 hasLocation W43868869641 @default.
- W4386886964 hasLocation W43868869642 @default.
- W4386886964 hasOpenAccess W4386886964 @default.
- W4386886964 hasPrimaryLocation W43868869641 @default.
- W4386886964 hasRelatedWork W2042893181 @default.
- W4386886964 hasRelatedWork W2060142842 @default.
- W4386886964 hasRelatedWork W2477169218 @default.
- W4386886964 hasRelatedWork W2588369178 @default.
- W4386886964 hasRelatedWork W2766413417 @default.
- W4386886964 hasRelatedWork W2767862884 @default.
- W4386886964 hasRelatedWork W2781166685 @default.
- W4386886964 hasRelatedWork W3022724713 @default.
- W4386886964 hasRelatedWork W3158966663 @default.
- W4386886964 hasRelatedWork W4320521215 @default.
- W4386886964 isParatext "false" @default.
- W4386886964 isRetracted "false" @default.
- W4386886964 workType "article" @default.